Indaptus Therapeutics (NASDAQ:INDP) Shares Up 15.3% – Here’s Why

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price traded up 15.3% during mid-day trading on Thursday . The stock traded as high as $3.65 and last traded at $3.7010. 462,507 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 623,553 shares. The stock had previously closed at $3.21.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Indaptus Therapeutics to a “hold” rating in a report on Saturday, June 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Indaptus Therapeutics currently has an average rating of “Sell”.

Indaptus Therapeutics Trading Down 9.7%

The stock has a market capitalization of $473.00 million, a PE ratio of -0.56 and a beta of 1.17. The stock’s fifty day simple moving average is $1.83 and its 200-day simple moving average is $2.18.

Indaptus Therapeutics (NASDAQ:INDP) last announced its earnings results on Thursday, August 13th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($1.57) by $1.55.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.